Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
Restart Life Sciences Corp (CSE: HEAL) is a publicly traded Canadian life sciences company dedicated to addressing today's health challenges with innovative wellness solutions. We are committed to forging a successful path through our unwavering dedication and achievements.
Restart Life Sciences Corp. is a dynamic and diverse organization dedicated to driving growth and fostering innovation in health and wellness. We approach business development as a complex puzzle, where each piece—whether an opportunity, challenge, or strategic decision—plays a pivotal role in advancing our objectives. Through the introduction of new products, strategic initiatives, and key partnerships, we are continuously building the framework that propels us toward achieving meaningful, long-term results.
Our team’s broad expertise, diverse perspectives, and creativity enable us to craft pioneering solutions that address the evolving needs of today’s health-conscious consumers. From advancing cognitive wellness solutions to expanding our market presence, every step we take is purposefully designed to fuel sustainable growth and deliver enduring value.
We would like to express our sincere gratitude to our investors for their unwavering support and trust in our vision. Your continued commitment empowers us to innovate, grow, and create a healthier, more prosperous future.
Together, we are shaping a remarkable and impactful journey.
Restart Life is at the forefront of developing natural remedies specifically tailored for individuals on the autism spectrum. Our focus is on creating innovative health foods that address the unique needs of this community. Recognizing the significant gap in the marketplace for effective, natural solutions, we are committed to creating high-quality products that promote overall wellness and support healthier lifestyles.
Restart Life Sciences is dedicated to developing health-related foods that promote both mind and body wellness for healthy living. Our mission is to create innovative, nutrient-rich products that support mental clarity, physical vitality, and overall well-being. By focusing on holistic nutrition, we aim to empower individuals to lead healthier, more balanced lives.
Restart Life Sciences and Brain Balls Inc entered into a Joint Venture to advance Brain Balls' innovative cognitive health products. The collaboration focuses on developing all-natural solutions targeting cognitive health. The joint venture highlights both companies' shared dedication to prioritizing consumer well-being and delivering results-driven wellness products.
Restart secured a production agreement with a co-packer, a recognized leader in the health food industry, who will serve as the official production partner for the Brain Balls and subsequent product lines. The co-packer operates a fully equipped production facility in British Columbia, Canada, which will be utilized to handle raw ingredients, package and ship, ensuring the highest quality standards for consumers.
We are partnered with KGK Science to conduct the Phase IIA clinical trial which is being carried out at the KGK facility in London, Ontario, Canada. This 10-person, open-label study will assess repetitive, oral low-dose psilocybin therapy for FXS. The Company intends to confirm changes in behavioural symptoms with state-of-the-art diagnostic and therapeutic mRNA and serotonin biomarker technology, combined with machine learning artificial intelligence (AI).
IP Conveyance Agreement with Ludwig Enterprises Inc. (LUDG). Under the terms of the agreement, in consideration of the assignment of the property (Intellectual property and patent of the mRNA neuro panel and serotonin assay, along with any and all data accumulated testing these assays), Ludwig issued to Restart 750,000 restricted shares of its common stock. In addition, for a period of 10 years, Ludwig shall pay Restart a 2.5-per-cent royalty on all revenue derived from the commercialization of the property up to the amount of $245,712 (U.S.) and 5 per cent on any revenue over this amount.
Restart Life secured the licensing rights to health-related trademarks, a strategic move that will play a role in the company's future brand development initiatives. This agreement aligns with Restart Life's efforts to strengthen its market position and expand its product portfolio.
Additional information to be announced.
Share Outstanding: 33,230,355
Reserved for Issuance: 14,023,708
(As of Feb 28/25)
Transfer Agent
Olympia Trust Company
Auditor
Kreston GTA LLP
Legal Counsel
Clark Wilson LLP
This website contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
Any forward-looking statements on this website include but are not limited to the statements related to the trade marks, the use of the trade marks, the license agreement, Company's position in the market and market growth.
The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various risk factors, including, but not limited to the ability to sell Company's products, appeal of the trademarks and Company's products to consumers, regulatory environment, taxes and tariffs.
The material assumptions used to develop forward-looking information include, but not limited to general business and economic conditions, financial markets conditions, the Company's ability to fund its operations, obtain licensees and/or permits (when required), develop, market and sell its products.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intention to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Copyright © 2025 Restart Life Sciences Corp.
All Rights Reserved. Disclaimer
Powered by ridepark.co
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.